Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...
EMERYVILLE, Calif., and LOS ANGELES, May 31, 2022 - Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, and City of Hope, one of ...
IL-15 enhances the growth and survival of GPC3 CAR T cells, improving their ability to target and fight solid tumors Study: Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback